The AVEA 2023 event was to recognise the remarkable accomplishments of vaccine and supply chain experts, organisations and cutting-edge technologies in Asia, with ultimate award winners determined through voting by industry experts, professionals and stakeholders in the vaccine community.
WuXi Vaccines stood out among the nominees for its commitment to advancing global vaccine accessibility, especially in low and middle-income countries.
Mr Jian Dong, CEO of WuXi Vaccines, commented: "We are deeply honoured to receive the Best Vaccine CMO Award of the Year for the second year."
"This prestigious accolade serves as a testament to WuXi Vaccines' unwavering dedication to furthering global health initiatives by providing end-to-end solutions that enable our partners to bring vital vaccine products to the market more efficiently."
Notably, WuXi Vaccines has played a crucial role in the fight against COVID-19 by manufacturing of hundreds of millions doses of COVID-19 vaccine, enabling them to supply the vaccine to more than 180 countries.
Recently, its first standalone vaccines CDMO site in Suzhou, China, has launched and successfully passed an on-site GMP audit by a global vaccine leader, which will accelerate global clients’ project timelines by providing high-quality end-to-end services for diversified vaccines.
Its Dundalk facility in Ireland has reached significant milestones, including the initiation of Tech Transfer (TT), and has made substantial progress in commissioning qualification and validation (CQV) activities.
The QC potency lab at the facility became operational in July 2020 and received the GMP certificate from the Ireland Health Products Regulatory Authority (HPRA) in July 2022.
